X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs GLENMARK PHARMA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER GLENMARK PHARMA PFIZER/
GLENMARK PHARMA
 
P/E (TTM) x 36.4 25.3 144.2% View Chart
P/BV x 5.4 4.0 135.5% View Chart
Dividend Yield % 0.6 0.3 208.4%  

Financials

 PFIZER   GLENMARK PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-18
GLENMARK PHARMA
Mar-17
PFIZER/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,365993 238.2%   
Low Rs1,625729 222.8%   
Sales per share (Unadj.) Rs430.3325.5 132.2%  
Earnings per share (Unadj.) Rs78.739.3 200.3%  
Cash flow per share (Unadj.) Rs93.248.7 191.5%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %1.00.2 431.7%  
Book value per share (Unadj.) Rs586.5159.2 368.4%  
Shares outstanding (eoy) m45.75282.17 16.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.62.6 175.3%   
Avg P/E ratio x25.321.9 115.7%  
P/CF ratio (eoy) x21.417.7 121.0%  
Price / Book Value ratio x3.45.4 62.9%  
Dividend payout %25.45.1 499.3%   
Avg Mkt Cap Rs m91,271242,991 37.6%   
No. of employees `0002.613.0 20.3%   
Total wages/salary Rs m3,14316,408 19.2%   
Avg. sales/employee Rs Th7,484.87,083.9 105.7%   
Avg. wages/employee Rs Th1,195.01,265.4 94.4%   
Avg. net profit/employee Rs Th1,369.1855.1 160.1%   
INCOME DATA
Net Sales Rs m19,68591,857 21.4%  
Other income Rs m1,143374 305.9%   
Total revenues Rs m20,82892,230 22.6%   
Gross profit Rs m5,00320,367 24.6%  
Depreciation Rs m6632,644 25.1%   
Interest Rs m42,373 0.2%   
Profit before tax Rs m5,47915,724 34.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m1,8783,827 49.1%   
Profit after tax Rs m3,60111,088 32.5%  
Gross profit margin %25.422.2 114.6%  
Effective tax rate %34.324.3 140.9%   
Net profit margin %18.312.1 151.5%  
BALANCE SHEET DATA
Current assets Rs m24,16768,746 35.2%   
Current liabilities Rs m9,54427,027 35.3%   
Net working cap to sales %74.345.4 163.6%  
Current ratio x2.52.5 99.5%  
Inventory Days Days5585 64.8%  
Debtors Days Days2996 30.0%  
Net fixed assets Rs m9,51424,132 39.4%   
Share capital Rs m458282 162.1%   
"Free" reserves Rs m26,37544,643 59.1%   
Net worth Rs m26,83244,925 59.7%   
Long term debt Rs m2545,363 0.1%   
Total assets Rs m36,900117,639 31.4%  
Interest coverage x1,305.57.6 17,120.7%   
Debt to equity ratio x01.0 0.1%  
Sales to assets ratio x0.50.8 68.3%   
Return on assets %9.811.4 85.4%  
Return on equity %13.424.7 54.4%  
Return on capital %20.419.1 106.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m2256,152 0.0%   
Fx outflow Rs m1,4898,084 18.4%   
Net fx Rs m-1,46648,068 -3.1%   
CASH FLOW
From Operations Rs m3,3186,574 50.5%  
From Investments Rs m-2,383-7,124 33.5%  
From Financial Activity Rs m-1,1045,432 -20.3%  
Net Cashflow Rs m-1691,992 -8.5%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 6.9 108.7%  
FIIs % 4.9 34.4 14.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 10.5 225.7%  
Shareholders   85,207 56,727 150.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   ORCHID PHARMA LTD  WYETH LTD  TORRENT PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Sep 21, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS